eli lily retatrutide Retatrutide, the next generation of GLP-1 drug from Lilly, helped participants lose an average of 71.2 pounds and reduce knee arthritis pain in a late-stage clinical trial, the company announced. In People lost up to 85
Description
10.1038/s44220-025-00390-x 18 de PaivaI
Which, at a high level, increases energy expenditure
joe bernstein Mogging
Gallbladder risk is a known tradeoff of GLP-1 therapy, and managing it well means working with a provider before and during treatment, not waiting until symptoms escalate
